BHSC — Bioharvest Sciences Income Statement
0.000.00%
Last trade - 00:00
- CA$143.53m
- CA$157.11m
- $5.50m
- 35
- 18
- 52
- 27
2018 April 30th | 2019 April 30th | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Interim Report | ARS | ARS | ARS | ARS |
Standards: | — | IFRS | IFRS | IFRS | IFRS |
Status: | fx Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0.396 | 2.1 | 5.5 |
Cost of Revenue | |||||
Gross Profit | — | — | 0.138 | 0.67 | 1.22 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | — | 4.36 | 6.56 | 10.6 | 16.1 |
Operating Profit | 0 | -4.36 | -6.17 | -8.49 | -10.6 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | — | -4.36 | -6.58 | -9.83 | -11.2 |
Net Income After Taxes | — | -4.36 | -6.58 | -9.83 | -11.2 |
Net Income Before Extraordinary Items | |||||
Net Income | — | -4.36 | -6.58 | -9.83 | -11.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 0 | -4.36 | -6.58 | -9.83 | -11.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | — | -0.028 | -0.018 | -0.023 | -0.025 |